Post COVID recurrent fever in children with polymorphisms in the innate immunity regulator, pyrin; MEFV gene, 2023, Levi Keller MD

[Mij]

Clinical Implications

• Children with persistent recurrent fevers after coronavirus disease 2019 (COVID-19) infection should be tested for polymorphisms in the innate immunity regulator, pyrin; gene MEFV. These children improve with daily colchicine therapy.

Emerging after the global transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), reports of prolonged symptoms after coronavirus disease 2019 (COVID-19) illnesses were reported. Now known as long-COVID or post-COVID by the U.S. Centers for Disease Control and Prevention, they are defined as persistent symptoms lasting longer than 12 weeks after the initial illness. A meta-analysis of pediatric patients observed 25% of pediatric patients experiencing long-COVID symptoms. Approximately 2% of these patients experienced recurrent fever.

We present 2 adolescent males with a pathogenic heterozygous mutation in the innate immunity regulator, pyrin: MEFV gene (p. A744S) in the setting of recurrent fever, fatigue, and brain fog after SARS-CoV-2 infection. Treatment with colchicine significantly improved these symptoms.

https://www.jaci-inpractice.org/article/S2213-2198(23)00281-7/fulltext

Colchicine therapy benefits pediatric long COVID patients suffering from recurring fever

https://www.news-medical.net/news/2...-patients-suffering-from-recurring-fever.aspx